Breaking News Nov 16, 2026 · 1 min read

FDA rejects Summit Therapeutics' lead lung cancer drug application; stock hits 52-week low

Summit Therapeutics' lead lung cancer drug application was rejected by the FDA, per Benzinga. Shares fell to a 52-week low on the news. The decision is a major regulatory setback for the company's core pipeline asset.

Source:
benzinga.com: https://www.benzinga.com/news/fda/26/11/63284061/summit-therapeutics-faces-fda-hurdle-for-lead-lung-cancer-drug-stock-tumbles

Not financial advice. For informational and educational purposes only.

Track your live portfolio alongside our daily institutional research

Connect your brokerage in 60 seconds and get full access to Position Tracker Substack research inside your dashboard.

Start your free trial →